glp-1 drugs and muscle loss GLP-1R agonists use | Acta Diabetologica GLP-1 Drugs & What They

Following the predefined inclusion and exclusion criteria, 36 studies were included in this systematic review and underwent qualitative analysis

Pfizers dose-optimization studies of once-daily formulations of danuglipron ( NCT06567327 and NCT06568731 ) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron

The most striking protective effects of SGLT2is were a marked reduction in hospitalization for heart failure and a remarkable reduced progression of chronic kidney disease

Oral dosing 14mg vs 2000mg ER, T2D first-line outcomes.

Simple Comparison between upcoming Monthly GLP-1s: By Amgen and Pfizer The Monthly Obesity Treatment Race Is Heating Up The next wave of obesity pharmacotherapy may not be about achieving greater efficacy aloneit may also be about achieving it with less frequent dosing